THE ZAMBIA Medicines Regulatory Authority says there is no need to be alarmed regarding the defective batches of Erythromycin Stearate BP 250mg tablets because it is not unusual in the pharmaceutical manufacturing space to have such occurrences. In a statement Monday, ZAMRA Senior Public Relations Officer Ludovic Mwape said such abnormalities also happened in other industries, affecting commodities like motor vehicles, mobile phones, and food. “ZAMRA wishes to assure the public that there is no need to be alarmed regarding the affected batches of Erythromycin Stearate BP 250mg tablets as none has been distributed by ZAMMSA. Further, in the pharmaceutical manufacturing space world over, such occurrences are not unusual. This happens also in other industries such as motor vehicles, mobile...